Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease
- Authors
- Kim, Seung Han; Cho, Kwang Bum; Chun, Hoon Jai; Lee, Sang Woo; Kwon, Joong Goo; Lee, Dong Ho; Kim, Sang Gyun; Jung, Hwoon-Yong; Kim, Ji Won; Lee, Joon Seong; Park, Hyojin; Choi, Suck Chei; Jee, Sam Ryong; Kim, Hyun-Soo; Ko, Kwang Hyun; Park, Seun Ja; Lee, Yong Chan; Park, Soo Heon; Kim, Ah Rong; Kim, Eun Ji; Park, Hyun Wook; Kim, Bong Tae; Song, Geun Seog
- Issue Date
- 8월-2021
- Publisher
- WILEY
- Citation
- ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.54, no.4, pp.402 - 411
- Indexed
- SCIE
SCOPUS
- Journal Title
- ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Volume
- 54
- Number
- 4
- Start Page
- 402
- End Page
- 411
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/127695
- DOI
- 10.1111/apt.16477
- ISSN
- 0269-2813
- Abstract
- Background Tegoprazan is a novel, fast- and long-acting potassium-competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non-erosive reflux disease (NERD), a type of gastroesophageal reflux disease. Aim To evaluate the efficacy and safety profiles of tegoprazan compared with those of a placebo in Korean patients with NERD. Methods In this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and placebo. These drugs were provided once daily for 4 weeks. The primary endpoint was the proportion of patients with complete resolution of major symptoms (both heartburn and regurgitation) for the last 7 days of the 4-week treatment period. Other outcomes related to efficacy, safety and tolerability were also evaluated. Results Among all, 42.5% (45/106), 48.5% (48/99) and 24.2% (24/99) of patients showed complete resolution of major symptoms at week 4 after receiving tegoprazan 50 mg, tegoprazan 100 mg, and placebo, respectively. Both doses of tegoprazan showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively). The complete resolution rates of heartburn and proportions of heartburn-free days (as other efficacy outcomes) were significantly higher in both tegoprazan groups than in the placebo group (P < 0.05 for all). No significant difference in the incidence of treatment-emergent adverse events were noted. Conclusions Tegoprazan 50 and 100 mg showed superior therapeutic efficacy compared with the placebo, as well as a favourable safety profile in patients with NERD. Registration number: ClinicalTrials.gov identifier NCT02556021.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.